A Study of Metformin With or Without Rapamycin as Maintenance Therapy After Induction Chemotherapy in Subjects With Pancreatic Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02048384|
Recruitment Status : Completed
First Posted : January 29, 2014
Last Update Posted : April 12, 2021
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Metastatic Pancreatic Adenocarcinoma||Drug: metformin alone (Arm A) Drug: metformin (Arm B) Drug: rapamycin (Arm B)||Phase 1|
Subjects with metastatic PDA who have received FOLFIRINOX or a gemcitabine-containing regimen and have achieved stable disease or better will be enrolled onto this study. Subjects should have had at least 6 months of chemotherapy and decline continuation of chemotherapy and should have stable disease or better on 2 scans taken at least 6 weeks apart. If applicable, subjects should also have a stable or declining CA19-9.
Twenty-two subjects will be randomized in a 1:1 ratio to metformin (Arm A) or metformin + rapamycin (Arm B). Subjects will be stratified according to their prior chemotherapy regimen: FOLFIRINOX or a gemcitabine-containing regimen.
Treatments will be administered orally on a 28 day cycle. Metformin will be administered 850mg twice daily and rapamycin will be administered 4mg daily.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||22 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||An Exploratory Study of Metformin With or Without Rapamycin as Maintenance Therapy After Induction Chemotherapy in Subjects With Metastatic Pancreatic Adenocarcinoma|
|Actual Study Start Date :||June 10, 2014|
|Actual Primary Completion Date :||February 2018|
|Actual Study Completion Date :||September 2019|
Experimental: A - metformin alone
metformin alone Arm A patients will receive metformin 850mg orally twice a day on a 28 day cycle.
Drug: metformin alone (Arm A)
Other Name: Glumetza, Fortamet, Riomet, Glucophage
Active Comparator: B - metformin + rapamycin
metformin + rapamycin Arm B patients will receive 850mg orally twice a day and rapamycin 4mg orally once a day on a 28 day cycle.
Drug: metformin (Arm B)
rapamycin + metformin
Other Name: Glumetza, Fortamet, Riomet, Glucophage
Drug: rapamycin (Arm B)
rapamycin + metformin
Other Name: Sirolimus, Rapamune
- safety and feasibility [ Time Frame: 1 year ]To determine the safety and feasibility of administering metformin with or without rapamycin in subjects with metastatic pancreatic ductal adenocarcinoma (PDA) after disease stabilization on chemotherapy.
- FDG uptake [ Time Frame: 1 year ]To evaluate fludeoxyglucose (FDG) uptake in metastatic PDA subjects treated with metformin with or without rapamycin.
- mTOR activity [ Time Frame: 1 year ]To measure mammalian target of rapamycin (mTOR) activity in peripheral blood mononuclear cells (PBMC) of subjects treated with metformin with or without rapamycin.
- estimation of RR, TTP, PFS, OS [ Time Frame: 1 year ]To estimate response rate (RR), time to progression (TTP), progression-free survival (PFS) and overall survival (OS) in subjects with metastatic PDA treated with metformin with or without rapamycin.
- CA19-9 measurement [ Time Frame: 1 year ]To measure tumor marker kinetics (CA 19-9) in subjects treated with metformin with or without rapamycin.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Histologically or cytologically confirmed metastatic pancreatic adenocarcinoma. Subjects with islet cell neoplasms are excluded.
- Have received 6 months of chemotherapy.
- Have stable disease for at least 6 months on the current regimen with the last 2 scans taken at least 6 months apart. Measurable disease not required.
- Eastern Cooperative Oncology Group performance status 0 or 1.
- Life expectancy of greater than 12 weeks.
- Adequate organ and marrow function.
- Oxygen saturation on room air > 92 % by pulse oximetry. (Subjects on intermittent or continuous supplemental oxygen are excluded).
- Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation.
- Ability to understand and the willingness to sign a written informed consent document.
- Receiving or has received any other investigational agents within 28 days prior to Day 1 of treatment in this study.
- Has undergone major surgery, other than diagnostic surgery (i.e. surgery done to obtain a biopsy for diagnosis or an aborted Whipple), within 28 days prior to Day 1 of treatment in this study.
- Known history of brain metastases unless previously treated and well controlled for at least 3 months (defined as stable clinically, no edema, no steroids).
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to metformin or rapamycin.
- Taking ketoconazole, voriconazole, itraconazole, erythromycin, telithromycin, clarithromycin, rifampin, rifabutin, bromocriptine, cimetidine, cisapride, clotrimazole, danazol, diltiazem, fluconazole, protease inhibitors (e.g., HIV and hepatitis C that include drugs such as ritonavir, indinavir, boceprevir, and telaprevir), metoclopramide, nicardipine, troleandomycin, verapamil, carbamazepine, phenobarbital, phenytoin, rifapentine, St. John's Wort (Hypericum perforatum), and grapefruit juice. Subjects on metformin will not be excluded.
- Has received any non-oncology live vaccine therapy used for prevention of infectious diseases for up to 28 days prior to or after the initiation of treatment in this study.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection (bacterial, viral, or fungal infection(s) requiring systemic therapy), symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- Has serious medical risk factors involving any of the major organ systems such that the Investigator considers it unsafe for the subject to receive an experimental research drug.
- Unhealed surgical wound or other clinically significant wound.
- Known history of chronic HIV, Hepatitis B or hepatitis C infections.
- Pregnant or breast feeding.
- Unwilling or unable to comply with study procedures.
- Cannot reliably swallow pills.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02048384
|United States, Arizona|
|Scottsdale Healthcare Hospitals DBA Honor Health|
|Scottsdale, Arizona, United States, 85258|
|United States, Maryland|
|Johns Hopkins SKCCC|
|Baltimore, Maryland, United States, 21231|
|Study Chair:||Dung Le, MD||Johns Hopkins SKCCC|
|Responsible Party:||Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|
|Other Study ID Numbers:||
NA_00090282 ( Other Identifier: JHMIRB )
|First Posted:||January 29, 2014 Key Record Dates|
|Last Update Posted:||April 12, 2021|
|Last Verified:||April 2021|
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Physiological Effects of Drugs